PCC Rokit (PCR) Q1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2026 earnings summary
21 May, 2026Executive summary
Revenue declined 15% year-over-year to 432.1 mln PLN, with EBITDA down 18.5% to 46.8 mln PLN and a net loss of 5.6 mln PLN, mainly due to weak demand and margin pressure in key segments.
All main business segments experienced lower sales volumes, with only the Polyurethanes/Poliuretany segment improving EBITDA by 73% despite lower sales, driven by improved margins.
The Group maintained operational stability through diversification, efficiency projects, and ongoing investments in energy optimization and production capacity.
Financial highlights
Consolidated revenue for 1Q2026 was 432.1 mln PLN, down 15% from 1Q2025; EBITDA was 46.8 mln PLN, a 19% decrease year-over-year; net income for 1Q2026 was -5.6 mln PLN.
Gross margin was 17.0% (down 0.8 p.p. y/y); EBITDA margin was 10.8% (down 0.5 p.p. y/y).
Net cash flow for 1Q2026 was -23.4 mln PLN; operating cash flow was 33.2 mln PLN (down 33% y/y); net cash outflow from investing was -73.6 mln PLN.
Net debt at end of 1Q2026 was 473.8 mln PLN; net debt/EBITDA ratio at 1.8x, within safe limits.
Outlook and guidance
Market conditions remain difficult, with low demand and high supply in key segments, and external factors such as geopolitical instability, energy prices, and macroeconomic volatility may impact future results.
Management expects continued operational cash flow generation to cover investments and debt service; investments in new production lines and energy efficiency are expected to support future competitiveness.
Latest events from PCC Rokit
- EBITDA and net profit fell sharply in 1-3Q 2024, driven by weak Chlorine Derivatives.PCR
Q3 20248 Apr 2026 - Revenue and profit dropped, but liquidity and investment activity remained strong.PCR
Q2 20248 Apr 2026 - EBITDA and net profit fell sharply in Q1 2025, despite higher revenue and ongoing investments.PCR
Q1 202520 Mar 2026 - EBITDA fell 28% and net profit 47% year-over-year, with chlorinated derivatives underperforming.PCR
Q4 202420 Mar 2026 - H1 2025 saw sharp declines in revenue, EBITDA, and profit, but liquidity remained resilient.PCR
Q2 202520 Mar 2026 - Net profit rose 5.6% to 40.8 million PLN despite a 6% revenue drop, aided by energy compensation.PCR
Q3 202520 Mar 2026 - 2025 saw lower revenue and profit but higher sales volume and continued investment.PCR
Q4 202520 Mar 2026